StockData

Longeveron vs Rafael

LGVN and RFL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and RFL compare

Longeveron is the larger company, worth 1.4 times as much as Rafael ($67.3M against $47.7M).

Rafael grew revenue faster over the last twelve months (−4.7% versus −42.7% for Longeveron).

Longeveron keeps more of each dollar of sales as profit, with a net margin of −1978% compared with −3391% at Rafael.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNRFL
Size and price
Market cap$67.3M$47.7M
Share price$2.11$0.913
Change, 1 year−69.0%−25.1%
Change, 5 years−99.9%−84.5%
Beta (5Y)1.440.58
Employees3717
StockData Score
Total score55
Valuation score01 (better)
Growth score01 (better)
Performance score02 (better)
Health score5 (better)1
Dividend score00
Valuation
P/S56.7×54.5× (better)
P/B6.5×0.7× (better)
FCF yield−30.5% (better)−62.9%
Growth
Revenue growth (TTM)−42.7%−4.7% (better)
Revenue growth, 5Y average−26.6%1.7% (better)
Profitability
Gross margin69.8%–
Operating margin−1993% (better)−3823%
Net margin−1978% (better)−3391%
FCF margin−1730% (better)−3431%
Return on equity−204%−36.9% (better)
Return on invested capital−1412%−61.5% (better)
Financial health
Debt / equity0.00–
Interest coverage–−100.3×
Current ratio2.63 (better)2.35
Altman Z-score−9.42−2.94 (better)
Piotroski F-score11
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.5%7.5%
Held by insiders43.8%39.2%
Short interest, % of float0.88%0.92%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.